Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px
Document › Details

MorphoSys AG. (10/22/14). "Press Release: MorphoSys to Receive Milestone Payment for Guselkumab Phase 3 Program".

Organisations Organisation MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX; Nasdaq: MOR)
  Group MorphoSys (Group)
  Organisation 2 Janssen Biotech Inc. (JBI)
  Group Johnson & Johnson (JnJ) (Group)
Products Product guselkumab (CNTO1959)
  Product 2 HuCAL®
Persons Person Sproll, Marlies (MorphoSys 201711– Special Adviser to CEO before 200510–201710 CSO)
  Person 2 Gutjahr-Löser, Claudia (MC Services 201710– Managing Director before MorphoSys 2002–2017 + Cassiopeia + Deutsche Bank)

MorphoSys AG (FSE: MOR; Prime Standard Segment, TecDAX, OTC: MPSYY) announced today that its collaborator Janssen Biotech, Inc. has initiated a phase 3 clinical trial in moderate to severe plaque-type psoriasis with the HuCAL antibody guselkumab (CNTO1959). The event triggered a clinical milestone payment to MorphoSys. Further financial details were not disclosed.

"Our therapeutic antibody pipeline represents the main value driver for MorphoSys and we are delighted to see our third HuCAL antibody advancing into late-stage clinical development. With every phase 3 start, the time when the first HuCAL antibody drug could enter the market gets closer" commented Dr. Marlies Sproll, Chief Scientific Officer of MorphoSys AG.

MorphoSys's clinical pipeline currently comprises 21 antibodies. Of these, 18 are programs that were initiated by partners, of which three are in phase 3 development, eight are in phase 2 and seven are in phase 1. From the company's proprietary portfolio, MOR202, which is being co-developed with Celgene, is in a phase 1/2a trial for multiple myeloma. MOR208 is currently being evaluated in phase 2 trials in B-ALL, NHL and CLL. The third proprietary compound, MOR103, partnered with GSK, has concluded a phase 1b/2a trial in rheumatoid arthritis and a phase 1b trial in multiple sclerosis.

Record changed: 2017-04-02


Picture EBD Group BIO-Europe Spring 2019 BES Wien Vienna Austria 273x168px

More documents for MorphoSys (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture [LSUS] – The Business Web Portal 600x60px

» top